ArticleJournal of virology2004
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00479999 (VRC 012), which is not on this map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults
Who cites it
67 citing papers in PubMed, 132 citations in OpenAlex.
- Trial
- Comparison of Immune Responses Elicited by Ad5F35-AEgp145 Alone or in Combination with rMVA-AEgp145.Viruses · 2026Article
- Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251.Nature communications · 2023Article
- Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus.Virology journal · 2020Article
- What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Rigorous Simian Immunodeficiency Virus Vaccine Trials Can Be Instructive.Cold Spring Harbor perspectives in biology · 2018Review
- Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.PloS one · 2017Article
- Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.Vaccine · 2015Article
- HIV DNA Vaccine: Stepwise Improvements Make a Difference.Vaccines · 2014Review
- HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.PloS one · 2014Article
- New directions for HIV vaccine development from animal models.Current opinion in HIV and AIDS · 2013Review
- Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection.Journal of virology · 2012Article
- Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.Current opinion in virology · 2011Review
- Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide.AIDS (London, England) · 2011Article
- Genetic immunization in the lung induces potent local and systemic immune responses.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.Clinical and vaccine immunology : CVI · 2010Article
- Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys.Virology · 2010Article
- Article
- Article
- Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge.Journal of virology · 2010Article
- Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.Journal of virology · 2010Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
Abstract
Because a strategy to elicit broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies has not yet been found, the role of an Env immunogen in HIV-1 vaccine candidates remains undefined. We sought to determine whether an HIV-1 Env immunogen genetically disparate from the Env of the challenge virus can contribute to protective immunity. We vaccinated Indian-origin rhesus monkeys with Gag-Pol-Nef immunogens, alone or in combination with Env immunogens that were either matched or mismatched with the challenge virus. These animals were then challenged with a pathogenic simian-human immunodeficiency virus. The vaccine regimen included a plasmid DNA prime and replication-defective adenoviral vector boost. Vaccine regimens that included the matched or mismatched Env immunogens conferred better protection against CD4(+) T-lymphocyte loss than that seen with comparable regimens that did not include Env immunogens. This increment in protective immunity was associated with anamnestic Env-specific cellular immunity that developed in the early days following viral challenge. These data suggest that T-lymphocyte immunity to Env can broaden the protective cellular immune response to HIV despite significant sequence diversity of the strains of the Env immunogens and can contribute to immune protection in this AIDS vaccine model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.